Institut Pasteur

Institut National De La Sante Et De La Recherche Medicale

Other

Thomson-csf

Roche Molecular Systems, Inc.

Institute Pasteur

Michel Favre

Dina Kremsdorf

Gerard Orth

Gerard Pehau-Arnaudet

Odile Croissant

Sylvie Beaudenon

Michel Villard

Christiane Baylac

Arnaud De Panafieu

G Erard Pehau-Arnaudet

A purified human papillomavirus gene selected from the group consisting of E1, E6-E7, L1, and L2, wherein said human papillomavirus is selected from the group consisting of HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2 and HPV-IP4. Polypeptides encoded by these genes. The polypeptides can be used in immunogenic compositions.

Immunogenic compositions of human papillomavirus and sera produced therefrom

The invention concerns human papillomavirus (HPV) DNA and more particularly the probes derived from these papillomaviruses, as well as the methods of detecting HPV using these probes. These human papillomaviruses are designated as HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2 and HPV-IP4.

Immunogenic compositions of human papillomavirus

The invention relates to papillomavirus probes derived from new DNA-HPVs deposited with the CNCM on the May 6, 1988 under the following filing numbers:

Immunogenic compositions and antibodies directed against human

Papillomavirus probe and a process for in vitro diagnosis of

The invention relates to papillomavirus probes derived from new DNA-HPVs deposited with the CNCM on the 6 May 1988 under the following filing numbers:

Purified polypeptide of human papillomavirus type 49 (HPV49) type 50

The invention relates to human papillomaviruses HPV, particularly to HPV-DNAs isolated from papillomaviruses HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2 and HPV-IP4. The invention also relates to DNA capable of hybridizing with the HPV-DNAs or fragments thereof, to kits containing distinct groups of probes containing one or more of these HPV-DNAs or fragments thereof, and to procedures for detecting and identifying HPV in tissue.

Papillomavirus probe and process for in vitro diagnosis of

The invention relates to papillomavirus probes derived from new DNA-HPVs deposited with the C.N.C.M. on May 6, 1988, under the following filing numbers:

Probes, diagnostic method and immunization method based on

Isolated DNA of human papillomavirus type 55 (HPV55)

Restriction maps of DNA derived from Human Papillomavirus Types 49, 50, 54, and 55 are disclosed as well as methods for providing recombinant forms of same.

Isolated DNA of human papillomavirus type 54(HPV54)

A process yielding a glass blank in the form of a rod intended for drawing an optical fiber of the kind of self-focussing fiber i.e. having a radial refractive index gradient, having features (substantially transparency or transmission efficiency) lower than those of the fibers intended for long distance communication but sufficient for middle distance transmission, and which exhibits a lower cost than known processes. In a first stage a phase separation yields a 'hard' phase (rich in silicon) and a 'soft' phase (poor in silicon and rich in impurities) due to the drawing of a rod from a bath of molten glass through a cooling system having a strong temperature gradient and creating a radial refractive index gradient. In a second stage the soft phase is leached, eliminating the impurities contained in the soft phase but keeping safe the radial gradient. In a third stage a consolidation treatment is a pure annealing treatment rendering the hard phase more homogeneous.

Growing community of inventors

Paris, France

Michel Favre